Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: FDA Starts November With A Bang

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.
Advertisement

Related Content

AbbVie's Fourth Humira Patent Settlement Allows Sandoz Biosimilar US Entry Eight Months After Amgen
Celltrion’s Biosimilar Rituximab Brings Indication Carve Outs To US FDA Panel Review
Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
Humira Biosimilar Settlement Could Be Model For Other Disputes
Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA
Apotex Moves To Block Coherus' Neulasta Biosimilar; Asks FDA To Require Patient Studies
Amgen Alleges 'Massive Conspiracy' By Employees Who Joined Coherus And KBI

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel